Chronic Kidney Disease

Vadadustat (Vafseo; Akebia Therapeutics Inc) is indicated for individuals with chronic kidney disease who have been receiving dialysis for at least 3 months.

Previously, felzartamab received orphan drug designation and breakthrough therapy designation for the treatment of primary membranous nephropathy.

In the study, investigators found superior kidney outcomes with injectable semaglutide (Ozempic) for individuals with type 2 diabetes and chronic kidney disease.

This agent can prevent the depletion of heparan sulphate in the endothelial glycocalyx layer of endothelial cells, ultimately protecting against vision loss and renal failure caused by diabetes.

According to the FDA review, patients with CKD receiving denosumab for osteoporosis who are on dialysis or have CKD-MBD are at the highest risk of severe hypocalcemia.

Increased waist circumference and high blood pressure can disrupt circadian rhythm, which can increase risk of progression to poor renal outcomes.

The update includes a recommended triple therapy with belimumab as a first line treatment for class III or IV lupus nephritis following the approvals of belimumab and voclosporin.

Tarpeyo is now the first fully FDA-approved treatment for primary immunoglobulin A nephropathy, based on measures of kidney function.

These drugs have interesting mechanisms, unique use, or may support expanded indications in the future.

Axitinib, cabozantinib, and lenvatinib are first-line treatment options.

Taurolidine and heparin (Defencath; CorMedix) is indicated to reduce catheter-related bloodstream infections for adults with kidney failure who are receiving chronic hemodialysis via central venous catheter

Session speaker Powell-Wiley explains how screening for SDOH in patients as cardiovascular-kidney-metabolic syndrome stages progress can help better understand their individual social needs.

The American Heart Association published a statement describing the cardiovascular-kidney-metabolic (CKM) construct, specifically highlighting treatment challenges for CKM syndrome.

A low carbohydrate diet plus a sodium glucose contransporter-2 (SGLT2) inhibitor was found to be safe and effective for weight loss and glycemic control in patients with diabetes and chronic kidney disease.

Individuals that are younger in age, Black, have low levels of education, and low income were associated with a lower chance of getting the flu shot each year.

Deep-rooted discrimination and stigma can contribute to stressors that worsen disease progression and access to care, according to experts.

Understanding the mechanisms leading to weight loss could help identify potential benefits for cardiorenal health in patients with chronic kidney disease.

Sodium-glucose cotransporter-2 inhibitors and sodium zirconium cyclosilicate may be paired with these kidney disease medications to reduce high serum potassium.

Exercise has the potential to improve physical performance and fitness at the very least, but a multidisciplinary intervention may work better for patients with chronic kidney disease.

Nephrotoxic care can be improved with better risk score assessment and provider education.

Improvements in AI could change the way pharmacists and providers interact with, and care for, patients.

The increased costs for patients with recurrent hyperkalemia were driven by the increased inpatient medical cost of additional time spent in the hospital following recurrence.

An analysis of the REVOLUTIONIZE II study data showed that there is an unmet need for long-term outpatient treatment of hyperkalemia in patients with CKD.

Outside of dialysis and transplantations, implantable artificial kidneys present an additional option for treating kidney disease, according to an expert.

Pharmacy Times will be at the American Society for Nephrology’s (ASN) 2023 Kidney Week Annual Meeting in Philadelphia, Pennsylvania, from November 2 to 5.

This marks the first time that experts have defined cardiovascular-kidney-metabolic syndrome, including the overlap of cardiovascular disease with kidney disease, type 2 diabetes, and obesity.

Twice-daily tenapanor tablets are recommended for patients with chronic kidney disease who are on dialysis, unresponsive or intolerant of any dose of a phosphate binder therapy.

Empagliflozin (Jardiance) demonstrated a 28% relative risk reduction, with an absolute risk reduction of 3.6% per patient-year at risk in the treatment of chronic kidney disease.

The sNDA is based on data that evaluated belzutifan (Welireg; Merck) compared to everolimus (Afinitor; Novartis) for the treatment of advanced renal cell carcinoma.